

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

---

Date of Report (Date of earliest event reported): November 12, 2014

**MARATHON PATENT GROUP, INC.**

(Exact Name of Registrant as Specified in Charter)

Nevada  
(State or other jurisdiction  
of incorporation)

000-54652  
(Commission File Number)

01-0949984  
(IRS Employer Identification No.)

11100 Santa Monica Blvd., Ste. 380  
Los Angeles, CA  
(Address of principal executive offices)

90025  
(Zip Code)

Registrant's telephone number, including area code: (800) 804-1690

(Former name or former address, if changed since last report)

Copies to:  
Harvey J. Kesner, Esq.  
61 Broadway, 32nd Floor  
New York, New York 10006  
Telephone: (212) 930-9700

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION**

**ITEM 7.01 REGULATION FD DISCLOSURE.**

On November 12, 2014, Marathon Patent Group, Inc., a Nevada corporation (the “Company”), issued a press release announcing its financial results for the third quarter ended September 30, 2014. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The furnishing of the information in this Current Report on Form 8-K is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information contained in this Current Report on Form 8-K constitutes material investor information that is not otherwise publicly available.

The Securities and Exchange Commission encourages registrants to disclose forward-looking information so that investors can better understand the future prospects of a registrant and make informed investment decisions. This Current Report on Form 8-K and exhibits may contain these types of statements, which are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and which involve risks, uncertainties and reflect the Registrant’s judgment as of the date of this Current Report on Form 8-K. Forward-looking statements may relate to, among other things, operating results and are indicated by words or phrases such as “expects,” “should,” “will,” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this Current Report on Form 8-K. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented within.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

(d) Exhibits.

The exhibit listed in the following Exhibit Index is furnished as part of this Current Report on Form 8-K.

| <u>Exhibit No.</u> | <u>Description</u>  |
|--------------------|---|
| 99.1               | Marathon Patent Group, Inc. Press Release dated November 12, 2014 |

---

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 12, 2014

**MARATHON PATENT GROUP, INC.**

By: /s/ Francis Knuettel II

Name: Francis Knuettel II

Title: Chief Financial Officer



## Marathon Patent Group, Inc. Announces Strong Third Quarter 2014 Financial Results

*Revenues for the Quarter increase to a record \$13.5 million  
GAAP net income of \$3.5 million, or \$0.61 per basic share and \$0.44 per diluted share*

**ALEXANDRIA, VA--(Marketwired – November 12, 2014) - Marathon Patent Group, Inc. (NASDAQ: MARA)** (“Marathon” or the “Company”), a patent licensing company, announced today financial results for the third quarter ended September 30, 2014. Highlights included:

- Revenues of \$13.5 million, up 255% from \$3.8 million from the prior quarter and more than 18 times higher than \$0.7 million in the third quarter last year
- Achieved GAAP net income for the first time in the Company’s history; GAAP net income totaled \$3.5 million or \$0.61 per basic share, as compared to GAAP net loss of \$1.6 million or (\$0.29) per diluted share in the prior quarter and GAAP net loss of \$0.9 million or (\$0.21) per basic share in the same quarter last year.
- Non-GAAP net income of \$6.9 million, or \$1.20 per share, up from Non-GAAP net income of \$1.2 million, or \$0.21 per diluted share in the prior quarter and Non-GAAP net loss of \$0.1 million, or (\$0.03) per diluted share in the comparable year-ago time period. A detailed reconciliation of GAAP to Non-GAAP results can be found at the end of the release.
- Cash and cash equivalents of \$5.6 million as of September 30, 2014, compared to \$6.5 million as of June 30, 2014 and \$3.6 million as of December 31, 2013.
- Accounts receivable of \$10.5 million as of September 30, 2014, compared to \$0.1 million as of June 30, 2014 and \$0.3 million as of December 31, 2013.
- Acquired 2 active patent portfolios consisting of 71 patents during the quarter.

Commenting on the Company’s third quarter financial results, Doug Croxall, Founder & Chief Executive Officer of Marathon, stated, “Marathon saw significant growth in the third quarter. Revenues of \$13.5 million were up 255% on a sequential basis and were more than 18 times higher year-over-year. This increase in our top-line can be attributed to strong execution of our patent licensing campaigns and the expansion of our patent portfolio, which we continue to diversify across a wide range of industries, technology areas and stages of maturity.”

Mr. Croxall continued, “In addition to our strong top-line growth, Marathon achieved GAAP profitability for the first time in the Company’s history. GAAP net income for the quarter totaled \$3.5 million, equating to \$0.61 per basic share and \$0.44 per diluted share. These results are indicative of our ability to execute our business plan, and we continue to strive to drive profitable growth and create value for our shareholders.”

“Looking forward, we believe that we will continue to make strides in the fourth quarter. At the end of October, a court in Germany ruled in favor of Marathon’s German subsidiary, MedTech Development Deutschland GmbH, by finding that Stryker GmbH & Co. infringes the asserted patents. As a result of this ruling, we expect to pursue an injunction within the borders of Germany. The German rulings and the unofficial English translations can be found on our web page,” Mr. Croxall concluded.

### Third Quarter 2014 Results

Revenue for the third quarter of 2014 totaled \$13.5 million, an increase from revenue of approximately \$0.7 million in the third quarter of 2013 and up 255% from \$3.8 million in revenue for the second quarter of 2014. The growth in revenue was driven by the issuance of larger one-time, non-recurring, non-exclusive, non-tangible licenses to five different entities and their affiliates, licenses to two of which accounted for nearly 100% of the Company’s revenues in the third quarter of 2014.

---

Direct costs of revenues for the third quarter of 2014 totaled \$5.6 million, an increase of approximately \$5.2 million from the third quarter 2013 and \$3.8 million, sequentially. Direct costs of revenues includes contingent payments to patent litigation attorneys, licensing advisors and previous patent owners along with non-contingent costs, principally legal fees and costs for technical experts, associated with enforcing the Company's patent rights and entering into settlement and licensing agreements. The increase in direct costs of revenues compared to the second quarter can be attributed to contingent payouts to counsel and former patent owners on significantly higher levels of revenue and various non-contingent costs associated with Marathon's patent rights (but exclusive of patent amortization expenses).

Gross profit for the quarter totaled \$7.9 million, or 58% of revenues, as compared to \$0.3 million, or 43% of revenues, in the comparable year-ago time period and \$2.1 million, or 54% of revenues, in the second quarter of 2014.

Total operating expenses, for the third quarter of 2014, including amortization of patents, compensation and related taxes, consulting and professional fees and other general and administrative fees were \$3.7 million, compared with total operating expenses of \$1.3 million in the third quarter of 2013 and total operating expenses of \$2.4 million in the second quarter of 2014.

Despite the significant increase in revenue, on a cash basis, cash operating expenses rose slightly from \$0.9 million in the second quarter of 2014 to \$1.0 million in the third quarter of 2014. Cash operating expenses were \$0.6 million for the third quarter of 2013. Total non-cash operating expenses for the third quarter of 2014 were \$2.7 million.

GAAP net income for the third quarter of 2014 was \$3.5 million, or \$0.61 per basic share, compared with a net loss of \$0.9 million, or a loss of (\$0.21) per diluted share, in the third quarter of 2013 and a net loss of \$1.6 million, or a loss of (\$0.29) per diluted share, in the second quarter of 2014.

On a non-GAAP basis, net income for the quarter totaled \$6.9 million, or \$1.20 per basic share, compared to non-GAAP net loss of \$0.1 million, or a loss of (\$0.03) per share, in the comparable year-ago time period, and non-GAAP net income of \$1.2 million, or \$0.21 per share, in the second quarter of 2014. A reconciliation of GAAP to non-GAAP financials can be found in the financial tables at the end of this press release.

As of September 30, 2014, cash and cash equivalents totaled \$5.6 million as compared to \$3.6 million as of December 31, 2013.

#### **Acquisition of Patents**

In August, Marathon entered into a patent purchase agreement to acquire a portfolio of patents from Clouding IP related to network and data management technology.

In September, Marathon acquired TLI Communications LLC, owner of US patent No. 6,038,295 (the "295 Patent"), an apparatus and method for recording, communicating and administering digital images. The 295 Patent is currently being asserted against 21 defendants in Eastern District of Virginia, including, but not limited to, Facebook, Google, Twitter, Yahoo, Pinterest, Apple and others. A claim construction hearing for all member cases in the TLI Communications patent litigation will be held on January 20, 2015 at the University of Virginia School of Law.

#### **Launch of Opus Patent Analysis Platform**

In September, Marathon announced the commercial launch of Opus™ Patent Analysis Platform. Opus includes a set of proprietary analytical tools that offer an unparalleled ability to both quickly evaluate a large patent portfolio as well as to deeply assess the strength of individual patents utilizing the unique Alpha Score™ system. Opus is available as a SaaS (software as a service) offering and is compatible with all computing platforms. For additional information, including pricing, visit the Opus website at [www.opus.marathonpg.com](http://www.opus.marathonpg.com).

---

## **Subsequent Events**

On October 10, 2014 Marathon entered into an acquisition agreement with MedTech Development LLC becoming the sole interest holder of OrthoPhoenix and TLIF as well as the sole shareholder and owner of MedTech Development Deutschland GmbH ("MedTech GmbH"). The patent portfolios included as part of this transaction cover inventions and technologies related to kyphoplasty, intervertebral inserts and heart valve technology. As previously announced, on October 30, 2014, a Germany Court ruled in favor of MedTech GmbH and found that Stryker GmbH & Co infringed the asserted patents. Marathon expects to pursue injunctive relief in the very near future.

On October 16, 2014, Marathon accepted subscriptions to issue 11% convertible notes in the aggregate principal amount of \$5,550,000 due 2018 with 35% warrant coverage. The notes and warrants, which on full conversion or exercise, at the initial conversion price of \$15.00 per share and \$16.50 per share for the warrants, could result in additional new shares being issued. The notes carry a mandatory conversion clause should the stock trade at a closing price of at least \$27.00 per share for any four trading days within an eight trading day period.

In addition, on October 22, 2014 Marathon's wholly-owned subsidiary Vantage Point Technology Inc. filed patent infringement lawsuits against Amazon.com Inc., Apple, Inc., Box, Inc., Dropbox, Inc., Google Inc., and SugarSync, Inc. in the US District Court for the Eastern District of Texas. Vantage Point is asserting infringement related to U.S. Patent No. 6,615,233 (the "233 Patent").

## **Investor Conference Call**

The Company will host a conference call to discuss the results featuring Chief Executive Officer Doug Croxall and Chief Financial Officer Frank Knuettel II today at 4:30 PM ET/1:30 PM PT.. To participate in the conference call, investors from the U.S. and Canada should dial (855) 327-6837 ten minutes prior to the scheduled start time. International callers should dial (631) 982-4565.

In addition, the call will be broadcast live over the Internet hosted at the Investor Relations section of the Company's website at [www.marathonpg.com](http://www.marathonpg.com) and will be archived online upon completion of the conference call. A telephonic replay of the conference call will also be available until 11:59 p.m. ET on Wednesday, November 19, 2014 by dialing (877) 870-5176 in the U.S. and Canada and (858) 384-5517 internationally and entering the passcode: 91106.

## **About Marathon Patent Group**

Marathon is a patent acquisition and monetization company. The Company acquires patents from a wide-range of patent holders from individual inventors to Fortune 500 companies. Marathon's strategy of acquiring patents that cover a wide-range of subject matter allows the Company to achieve diversity within its patent asset portfolio. Marathon generates revenue with its diversified portfolio through actively managed concurrent patent rights enforcement campaigns. This approach is expected to result in a long-term, diversified revenue stream. To learn more about Marathon Patent Group, visit [www.marathonpg.com](http://www.marathonpg.com).

## **Safe Harbor Statement**

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the effect of the global economic downturn on technology companies, the ability to successfully develop licensing programs and attract new business, rapid technological change in relevant markets, changes in demand for current and future intellectual property rights, legislative, regulatory and competitive developments addressing licensing and enforcement of patents and/or intellectual property in general and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other filings with the Securities and Exchange Commission (the "SEC") discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

The results achieved in the most recent quarter are not necessarily indicative of the results to be achieved by us in any subsequent quarters, as it is currently anticipated that Marathon Patent Group's financial results will vary, and may vary significantly, from quarter to quarter. This variance is expected to result from a number of factors, including risk factors affecting our results of operations and financial condition referenced above, and the particular structure of our licensing transactions, which may impact the amount of inventor royalties and contingent legal fees expenses we incur period to period.

---

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

## **CONTACT INFORMATION**

### **Investor Relations Contact:**

Marathon Patent Group  
Daniel Gelbtuch  
Chief Marketing Officer  
917-509-9582  
daniel@marathonpg.com

Addo Communications  
Lasse Glassen  
Director  
424-238-6249  
lasseg@addocommunications.com

---

**MARATHON PATENT GROUP, INC. AND SUBSIDIARIES**  
**CONSOLIDATED BALANCE SHEETS**

|   | September 30,<br>2014<br>(Unaudited) | December 31,<br>2013 |
|---|--------------------------------------|----------------------|
| <b>ASSETS</b>   |                                      |                      |
| Current assets:   |                                      |                      |
| Cash  | \$ 5,556,584                         | \$ 3,610,262         |
| Accounts receivable - net   | 10,510,000                           | 270,000              |
| Marketable securities - available for sale securities   | -                                    | 6,250                |
| Prepaid expenses and other current assets   | 340,456                              | 752,931              |
| Total current assets  | <u>16,407,040</u>                    | <u>4,639,443</u>     |
| Other assets:   |                                      |                      |
| Property and equipment, net   | 13,026                               | 13,640               |
| Intangible assets, net  | 33,514,365                           | 6,157,659            |
| Deferred tax assets   | 1,949,401                            | -                    |
| Goodwill  | 1,606,800                            | 2,144,488            |
| Total other assets  | <u>37,083,592</u>                    | <u>8,315,787</u>     |
| Total Assets  | <u>\$ 53,490,632</u>                 | <u>\$ 12,955,230</u> |
| <b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>   |                                      |                      |
| Current liabilities:  |                                      |                      |
| Accounts payable and accrued expenses   | \$ 5,665,707                         | \$ 754,945           |
| Clouding IP earn out - current portion  | 2,148,000                            | -                    |
| Income tax payable  | 467,997                              | -                    |
| Notes payable   | 6,062,500                            | -                    |
| Total current liabilities   | <u>14,344,204</u>                    | <u>754,945</u>       |
| Long-term liabilities   |                                      |                      |
| Clouding IP earn out, long-term portion   | 10,967,000                           | -                    |
| Total long-term liabilities   | <u>10,967,000</u>                    | <u>-</u>             |
| Liabilities of discontinued operations  | -                                    | 30,664               |
| Total liabilities   | <u>25,311,204</u>                    | <u>785,609</u>       |
| Stockholders' Equity:   |                                      |                      |
| Series A Convertible Preferred Stock, \$.0001 par value, 50,000,000 shares authorized: 1,008,194 and 0 issued and outstanding at September 30, 2014 and December 31, 2013 | 101                                  | -                    |
| Series B Convertible Preferred Stock, \$.0001 par value, 50,000,000 shares authorized: 391,000 and 0 issued and outstanding at September 30, 2014 and December 31, 2013   | 39                                   | -                    |
| Common stock, (\$.0001 par value; 200,000,000 shares authorized; 5,799,448 and 5,489,593 issued and outstanding at September 30, 2014 and December 31, 2013)              | 580                                  | 549                  |
| Additional paid-in capital  | 35,709,773                           | 22,673,287           |
| Accumulated other comprehensive income - marketable securities available for sale   | -                                    | (6,250)              |
| Accumulated deficits  | <u>(7,531,065)</u>                   | <u>(10,487,469)</u>  |
| Total Marathon Patent Group, Inc. equity  | 28,179,428                           | 12,180,117           |
| Non-controlling interest in subsidiary  | -                                    | (10,496)             |
| Total stockholders' equity  | <u>28,179,428</u>                    | <u>12,169,621</u>    |
| Total liabilities and stockholders' equity  | <u>\$ 53,490,632</u>                 | <u>\$ 12,955,230</u> |

The accompanying notes are an integral part of these consolidated financial statements.

**MARATHON PATENT GROUP, INC. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF OPERATIONS**

|   | FOR THE THREE<br>MONTHS<br>ENDED<br>SEPTEMBER 30,<br>2014<br><u>(Unaudited)</u> | FOR THE<br>THREE<br>MONTHS<br>ENDED<br>SEPTEMBER 30,<br>2013<br><u>(Unaudited)</u> | FOR THE NINE<br>MONTHS<br>ENDED<br>SEPTEMBER 30,<br>2014<br><u>(Unaudited)</u> | FOR THE NINE<br>MONTHS<br>ENDED<br>SEPTEMBER 30,<br>2013<br><u>(Unaudited)</u> |
|---|---|--|--|--|
| Revenues  | \$ 13,455,472   | \$ 710,500   | \$ 20,059,972  | \$ 2,235,479   |
| Cost of revenues (cost of revenue is exclusive of patent amortization expenses)                   | <u>5,584,542</u>  | <u>403,013</u>   | <u>8,448,954</u>   | <u>687,638</u>   |
| Gross profit  | <u>7,870,930</u>  | <u>307,487</u>   | <u>11,611,018</u>  | <u>1,547,841</u>   |
| Expenses  |   |  |  |  |
| Amortization of patents and website   | 1,480,311   | 384,977  | 2,872,638  | 860,657  |
| Compensation and related taxes  | 824,165   | 470,786  | 2,266,283  | 1,938,814  |
| Consulting fees   | 785,601   | 269,012  | 1,550,155  | 444,921  |
| Professional fees   | 408,280   | 116,373  | 933,751  | 564,597  |
| General and administrative  | 166,216   | 108,278  | 380,400  | 315,260  |
| Total operating expenses  | <u>3,664,573</u>  | <u>1,349,426</u>   | <u>8,003,227</u>   | <u>4,124,249</u>   |
| Operating income (loss) from continuing operations  | <u>4,206,357</u>  | <u>(1,041,939)</u>   | <u>3,607,791</u>   | <u>(2,576,408)</u>   |
| Other income (expenses)   |   |  |  |  |
| Other income  | 4,187   | -  | 4,187  | -  |
| Other expense   | (24,994)  | -  | (25,764)   | -  |
| Realized loss - available for sale  | -   | (38,819)   | -  | (38,819)   |
| Impairment of goodwill  | (2,144,488)   | -  | (2,144,488)  | -  |
| Interest income   | 138   | 474  | 632  | 1,114  |
| Interest expense  | -   | (243)  | (20)   | (702)  |
| Total other income (expenses)   | <u>(2,165,157)</u>  | <u>(38,588)</u>  | <u>(2,165,453)</u>   | <u>(38,407)</u>  |
| Income (loss) from continuing operations before benefit for income taxes                          | 2,041,200   | (1,080,527)  | 1,442,338  | (2,614,815)  |
| Income tax benefit  | <u>1,481,404</u>  | <u>-</u>   | <u>1,481,404</u>   | <u>-</u>   |
| Income (loss) from continuing operations  | 3,522,604   | (1,080,527)  | 2,923,742  | (2,614,815)  |
| Discontinued operations:  |   |  |  |  |
| Income from discontinued operations, net of tax   | <u>-</u>  | <u>145,207</u>   | <u>-</u>   | <u>263,460</u>   |
| Net Income (loss)   | 3,522,604   | (935,320)  | 2,923,742  | (2,351,355)  |
| Deemed dividends related to beneficial conversion feature of Series A Convertible Preferred Stock | <u>-</u>  | <u>-</u>   | <u>(1,271,492)</u>   | <u>-</u>   |
| Net income (loss) available to common shareholders  | 3,522,604   | (935,320)  | 1,652,250  | (2,351,355)  |
| Income (loss) per common share, basic:  |   |  |  |  |
| Income (loss) from continuing operations  | \$ 0.61   | \$ (0.21)  | \$ 0.52  | \$ (0.60)  |
| Income from discontinued operations   | <u>-</u>  | <u>0.03</u>  | <u>-</u>   | <u>0.06</u>  |
|   | <u>\$ 0.61</u>  | <u>\$ (0.18)</u>   | <u>\$ 0.52</u>   | <u>\$ (0.54)</u>   |
| Income (loss) per common share, diluted:  |   |  |  |  |
| Income (loss) from continuing operations  | \$ 0.44   | \$ (0.21)  | \$ 0.39  | \$ (0.60)  |
| Income from discontinued operations   | <u>-</u>  | <u>0.03</u>  | <u>-</u>   | <u>0.06</u>  |
|   | <u>\$ 0.44</u>  | <u>\$ (0.18)</u>   | <u>\$ 0.39</u>   | <u>\$ (0.54)</u>   |
| WEIGHTED AVERAGE COMMON SHARES  |   |  |  |  |
| OUTSTANDING - Basic   | <u>5,750,250</u>  | <u>5,227,840</u>   | <u>5,598,687</u>   | <u>4,330,208</u>   |
| OUTSTANDING - Diluted   | <u>7,983,227</u>  | <u>5,227,840</u>   | <u>7,463,252</u>   | <u>4,330,208</u>   |

The accompanying notes are an integral part of these consolidated financial statements.



**MARATHON PATENT GROUP, INC. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**

|  | FOR THE NINE<br>MONTHS<br>ENDED<br>SEPTEMBER 30,<br>2014<br><u>(Unaudited)</u> | FOR THE NINE<br>MONTHS<br>ENDED<br>SEPTEMBER 30,<br>2013<br><u>(Unaudited)</u> |
|--|--|--|
| Cash flows from operating activities:  |  |  |
| Net income (loss)  | \$ 2,923,742   | \$ (2,351,355)   |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:           |  |  |
| Depreciation   | 4,357  | 1,944  |
| Amortization of patents and website  | 2,872,638  | 860,657  |
| Amortization of expenses connected to equity to be issued for services                                       | 355,711  | 121,564  |
| Net reversal of expense related to forfeiture of unvested stock  | (179,708)  | -  |
| Impairment of Goodwill   | 2,144,488  | -  |
| Deferred tax asset   | (1,949,401)  | -  |
| Income tax payable   | 467,997  | -  |
| Stock based compensation relating to warrants  | 31,182   | 94,930   |
| Stock based compensation   | 2,070,813  | 1,347,774  |
| Non-cash revenue   | -  | (1,000,000)  |
| Non-cash other income  | (3,930)  | -  |
| Realized loss - available for sale   | -  | 38,819   |
| Gain on sale of assets of discontinued operations  | -  | (168,216)  |
| Other non-cash adjustments   | 24,994   | -  |
| Changes in operating assets and liabilities  |  |  |
| Accounts receivable  | (10,182,950)   | (330,000)  |
| Assets of discontinued operations - current portion  | -  | 82,145   |
| Prepaid expenses and other current assets  | (207,182)  | 39,000   |
| Accounts payable and accrued expenses  | 4,860,286  | 315,394  |
| Net cash provided by (used in) operating activities  | <u>3,233,037</u>   | <u>(947,344)</u>   |
| Cash flows from investing activities:  |  |  |
| Acquisition of patents   | (6,850,800)  | (1,950,000)  |
| Purchase of property, equipment, and other intangible assets   | (24,903)   | (10,000)   |
| Proceeds received from sale of marketable securities   | -  | 129,397  |
| Sale of real estate property (discontinued operations)   | -  | 1,052,320  |
| Capitalized cost related to improvements of real estate property (discontinued operations)                   | -  | (16,750)   |
| Net cash used in investing activities  | <u>(6,875,703)</u>   | <u>(795,033)</u>   |
| Cash flows from financing activities:  |  |  |
| Payment on note payable in connection with the acquisition of IP Liquidity                                   | (937,500)  | -  |
| Payment on note payable in connection with the acquisition of Cyberfone Systems, LLC                         | -  | (500,000)  |
| Proceeds from sale of preferred and common stock, net of issuance costs                                      | 6,388,266  | 5,752,596  |
| Cash received upon exercise of warrant   | 138,222  | -  |
| Net cash provided by financing activities  | <u>5,588,988</u>   | <u>5,252,596</u>   |
| Net increase in cash   | 1,946,322  | 3,510,219  |
| Cash at beginning of period  | <u>3,610,262</u>   | <u>2,354,169</u>   |
| Cash at end of period  | <u>\$ 5,556,584</u>  | <u>\$ 5,864,388</u>  |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:  |  |  |
| Cash paid for:   |  |  |
| Interest   | <u>\$ 20</u>   | <u>\$ 702</u>  |
| SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:                                      |  |  |
| Common stock issued in connection with the acquisition of Cyberfone Systems, LLC                             | <u>\$ -</u>  | <u>\$ 2,280,000</u>  |
| Common stock issued in connection with the acquisition of Clouding Corp                                      | <u>\$ 281,000</u>  | <u>\$ -</u>  |
| Earn-out liability in connection with the acquisition of Clouding Corp                                       | <u>\$ 13,119,000</u>   | <u>\$ -</u>  |
| Common stock granted in connection with the acquisition of TLI Communications, LLC                           | <u>\$ 817,800</u>  | <u>\$ -</u>  |
| Series B Convertible Preferred Stock issued in connection with the acquisition of Dynamic Advances LLC       | <u>\$ 1,403,690</u>  | <u>\$ -</u>  |
| Series B Convertible Preferred Stock issued in connection with the acquisition of IP Liquidity Ventures, LLC | <u>\$ 1,403,690</u>  | <u>\$ -</u>  |

|   |                     |                     |
|---|---------------------|---------------------|
| Common stock issued in connection with the acquisition of Selene Communication Technologies   | \$ 980,000          | \$ -                |
| Value of warrants pertaining to equity issuance   | <u>\$ 11,595</u>    | <u>\$ 11,595</u>    |
| Notes payable issued in connection with the acquisition of IP Liquidity Ventures, LLC, Dynamic Advances, LLC, Selene Communication Technologies, LLC, and Clouding Corp | <u>\$ 7,000,000</u> | <u>\$ -</u>         |
| Common Stock issued for prepaid services  | <u>\$ (298,301)</u> | <u>\$ 441,256</u>   |
| Acquisition of patents in connection with a non-cash settlement   | <u>\$ -</u>         | <u>\$ 1,000,000</u> |

The accompanying notes are an integral part of these consolidated financial statements.

---

**Marathon Patent Group**  
**Reconciliation of GAAP to Non-GAAP Financials**  
**(Unaudited)**

|  | <b>For the Three Months ended</b> |                          |                           |
|--|-----------------------------------|--------------------------|---------------------------|
|  | <b>Sept. 30,<br/>2014</b>         | <b>June 30,<br/>2014</b> | <b>Sept. 30,<br/>2013</b> |
| Net Income   | \$ 3,522,604                      | \$ (1,589,743)           | \$ (935,320)              |
| Non-GAAP   |                                   |                          |                           |
| Provision for Income Taxes                         | (1,481,404)                       | -                        | -                         |
| Amortization of Intangible Assets                  | 1,479,588                         | 938,679                  | 495,291                   |
| Equity-based Compensation                          | 1,222,086                         | 554,356                  | 306,333                   |
| BCF  | -                                 | 1,271,942                | -                         |
| Impairment of Goodwill                             | 2,144,488                         | -                        | -                         |
| Depreciation                                       | 1,452                             | 1,417                    | 833                       |
| Non-GAAP Net Income                                | \$ 6,888,814                      | \$ 1,176,650             | \$ (132,863)              |
| Weighted Average Common Shares Outstanding (Basic) | 5,750,250                         | 5,508,323                | 4,330,208                 |
| Non-GAAP Net Income per Common Share (Basic)       | \$ 1.20                           | \$ 0.21                  | \$ (0.03)                 |

**INFORMATION ABOUT NON-GAAP FINANCIAL MEASURES.** As used herein, "GAAP" refers to accounting principles generally accepted in the United States of America. To supplement our consolidated financial statements prepared and presented in accordance with GAAP, this earnings release includes financial measures, including (1) non-GAAP net income and (2) non-GAAP Earnings Per Share ("EPS"), that are considered non-GAAP financial measures as defined in Rule 101 of Regulation G promulgated by the Securities and Exchange Commission. Generally, a non-GAAP financial measure is a numerical measure of a company's historical or future performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

We use these non-GAAP financial measures for internal financial and operational decision making purposes and as a means to evaluate period-to-period comparisons of the performance and results of operations of our core business. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the performance of our core business by excluding non-cash stock compensation charges, non-cash patent amortization charges and excess benefit related non-cash tax expense that may not be indicative of our recurring core business operating results. These non-GAAP financial measures also facilitate management's internal planning and comparisons to our historical performance and liquidity. We believe these non-GAAP financial measures are useful to investors as they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making and are used by our institutional investors and the analyst community to help them analyze the performance and operational results of our core business.

**Non-GAAP Net income and EPS.** We define non-GAAP net income as net income calculated in accordance with GAAP, plus non-cash stock compensation charges, non-cash patent amortization charges and excess benefit related non-cash tax expense. Non-GAAP EPS is defined as non-GAAP net income divided by the weighted average outstanding shares, on a fully diluted basis, calculated in accordance with GAAP, for the respective reporting period.

*Due to the inherent volatility in stock prices, the use of estimates and assumptions in connection with the valuation and expensing of share-based awards and the variety of award types that companies can issue under FASB ASC Topic 718, management believes that providing a non-GAAP financial measure that excludes non-cash stock compensation allows investors to make meaningful comparisons between our recurring core business operating results and those of other companies, as well as providing our management with a critical tool for financial and operational decision making and for evaluating our own period-to-period recurring core business operating results. Similarly, due to the variability associated with the timing and amount of patent acquisition payments and estimates inherent in the capitalization and amortization of patent acquisition costs, management believes that providing a non-GAAP financial measure that excludes non-cash patent amortization charges allows investors to make meaningful comparisons between our recurring core business operating results and those of other companies, and also provides our management with a useful tool for financial and operational decision making and for evaluating our own period-to-period recurring core business operating results. Lastly, for financial reporting purposes, tax expense is required to be calculated without the excess tax benefit related to the exercise and vesting of equity-based incentive awards, however, the deduction related to the exercise and vesting of equity-based incentive awards is available to offset taxable income on our consolidated tax returns. Accordingly, the non-cash tax expense calculated without the excess benefit for financial statement purposes is credited to additional paid-in capital, not taxes payable, and does not represent a cash tax obligation. Management believes that providing a non-GAAP financial measure that excludes excess benefit related non-cash tax expense allows investors to assess our net results and the economic impact of income taxes based largely on cash tax obligations, make more meaningful comparisons between our recurring core business net results and those of other companies, and also provides our management with a useful tool for financial and operational decision making and for evaluating our own period-to-period recurring core business net results.*

*There are a number of limitations related to the use of non-GAAP net income and EPS versus net income and EPS calculated in accordance with GAAP. For example, non-GAAP net income excludes significant non-cash stock compensation charges, non-cash patent amortization charges and excess benefit related non-cash tax expense that are recurring, and will continue to be recurring for the foreseeable future. In addition, non-cash stock compensation is a critical component of our employee compensation programs and non-cash patent amortization reflects the cost of certain patent portfolio acquisitions, amortized on a straight-line basis over the estimated economic useful life of the respective patent portfolio, and may reflect the acceleration of amortization related to recoupable up-front patent portfolio acquisition costs. Management compensates for these limitations by providing specific information regarding the GAAP amounts excluded from non-GAAP net income and EPS and evaluating non-GAAP net income and EPS in conjunction with net income and EPS calculated in accordance with GAAP.*

*The table set forth above provides a reconciliation of the non-GAAP financial measures presented to the most directly comparable financial*

*measures prepared in accordance with GAAP.*